12.18 USD
+0.31 (+2.61%)
AMRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AMRX has an average financial health and profitability rating. AMRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year AMRX was profitable.
AMRX had a positive operating cash flow in the past year.
In multiple years AMRX reported negative net income over the last 5 years.
AMRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AMRX has a Return On Assets of 0.16%. This is in the better half of the industry: AMRX outperforms 77.49% of its industry peers.
AMRX's Return On Invested Capital of 10.43% is amongst the best of the industry. AMRX outperforms 89.53% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMRX is below the industry average of 12.85%.
The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
AMRX has a better Profit Margin (0.20%) than 77.49% of its industry peers.
AMRX has a Operating Margin of 12.32%. This is amongst the best in the industry. AMRX outperforms 85.34% of its industry peers.
In the last couple of years the Operating Margin of AMRX has grown nicely.
AMRX has a Gross Margin of 36.76%. This is comparable to the rest of the industry: AMRX outperforms 59.16% of its industry peers.
In the last couple of years the Gross Margin of AMRX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
AMRX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AMRX has been reduced compared to 1 year ago.
AMRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMRX has been reduced compared to a year ago.
2.2 Solvency
AMRX has an Altman-Z score of 1.85. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.85, AMRX perfoms like the industry average, outperforming 57.59% of the companies in the same industry.
The Debt to FCF ratio of AMRX is 11.13, which is on the high side as it means it would take AMRX, 11.13 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 11.13, AMRX is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.85 |
ROIC/WACC1.01
WACC10.31%
2.3 Liquidity
A Current Ratio of 2.13 indicates that AMRX has no problem at all paying its short term obligations.
AMRX has a Current ratio (2.13) which is in line with its industry peers.
A Quick Ratio of 1.42 indicates that AMRX should not have too much problems paying its short term obligations.
AMRX has a worse Quick ratio (1.42) than 64.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
Measured over the past years, AMRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.63% on average per year.
The Revenue has grown by 16.73% in the past year. This is quite good.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y40.69%
EPS Next 2Y28.74%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.24, the valuation of AMRX can be described as correct.
Based on the Price/Earnings ratio, AMRX is valued cheaper than 85.34% of the companies in the same industry.
AMRX is valuated rather cheaply when we compare the Price/Earnings ratio to 26.34, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 12.67 indicates a correct valuation of AMRX.
Based on the Price/Forward Earnings ratio, AMRX is valued cheaply inside the industry as 84.29% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, AMRX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.24 | ||
| Fwd PE | 12.67 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaply inside the industry as 86.91% of the companies are valued more expensively.
84.82% of the companies in the same industry are more expensive than AMRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.19 | ||
| EV/EBITDA | 10.24 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AMRX has a very decent profitability rating, which may justify a higher PE ratio.
AMRX's earnings are expected to grow with 24.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)1.53
EPS Next 2Y28.74%
EPS Next 3Y24.22%
5. Dividend
5.1 Amount
No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AMRX (12/9/2025, 10:32:09 AM)
12.18
+0.31 (+2.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.3%
Inst Owner Change6.11%
Ins Owners46.29%
Ins Owner Change-4.88%
Market Cap3.83B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts82
Price Target13.6 (11.66%)
Short Float %4.21%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)11.11%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.29%
EPS NY rev (1m)0.11%
EPS NY rev (3m)7.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.24 | ||
| Fwd PE | 12.67 | ||
| P/S | 1.3 | ||
| P/FCF | 16.19 | ||
| P/OCF | 11.68 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.24 |
EPS(TTM)0.75
EY6.16%
EPS(NY)0.96
Fwd EY7.89%
FCF(TTM)0.75
FCFY6.18%
OCF(TTM)1.04
OCFY8.56%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.4
PEG (5Y)1.53
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.85 |
F-Score7
WACC10.31%
ROIC/WACC1.01
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.69%
EPS Next 2Y28.74%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.19%
EBIT Next 3Y10.22%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
What is the financial health of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
What is the earnings growth outlook for AMNEAL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.69% in the next year.